BioCentury | Apr 4, 2011
Strategy

Half-A-Loaf Dilemma

...evidence to support the rationale," he added. This includes a pair of Phase II programs: CEP-18770...
...with DNA repair mismatch. According to Cephalon's 10-K filing, the company has data showing that CEP-18770...
...treatment with two or more tyrosine kinase inhibitors (TKIs), regardless of mutation status MAA 2H11 CEP-18770...
BioCentury | Mar 28, 2011
Product Development

Buying proof of concept

...tyrosine kinase inhibitor, such as Nexavar sorafenib or Tykerb lapatinib. Cephalon's internal cancer pipeline includes CEP-18770...
BioCentury | Jul 24, 2008
Targets & Mechanisms

Purely Proteasome

...cell lymphoma Market Proteolix Inc. Carfilzomib (PR-171) MM; solid tumors Phase II Cephalon Inc. (NASDAQ:CEPH) CEP-18770...
BioCentury | Feb 4, 2008
Product Development

Proteasome inhibitors on deck

...Ph II Carfilzomib (PR-171) Relapsed solid tumors Ph Ib/II PR-047 oral Cancer Preclin Cephalon (NASDAQ:CEPH) CEP-18770...
Items per page:
1 - 4 of 4